

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Toshio MIYATA et al. : **Mail Stop: PCT**
Serial No. 10/581,255 : Attorney Docket No. 2006_0834A
Filed May 31, 2006 :

INHIBITOR OF PROTEIN MODIFICATION
PRODUCTS FORMATION
[Corresponding to PCT/JP2004/018038
Filed December 3, 2004]

THE UNITED STATES PATENT AND TRADEMARK OFFICE
TO OBTAIN A PATENT IN THE UNITED STATES
FILES FOR THE NATIONAL STAGE DEPOSIT
ACCOUNT NO. 23-0975

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- ☐ each U.S. Patent and U.S. Patent application publication;
- ☐ each reference previously cited in the international application PCT/_____; and/or
- ☐ each reference previously cited in prior parent application Serial No. _____.

1a. [X] This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, **or**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.S./

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

- 1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) ☐ the certification of paragraph 2 below is provided, or
(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

- 1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

**the certification of paragraph 2 below is provided, and
the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**

2. It is hereby certified


- a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
 - b. ☐ a foreign patent office search report (in the English language) submitted herewith,
 - c. ☒ the concise explanation contained in the specification of the present application at pages 1 and 14,
 - d. ☐ the concise explanation set forth in the attached English language abstract,
 - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☐ A foreign patent office search report citing one or more of the references is enclosed.
6. ☐ Statement Under 37 CFR 1.704(d)

Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign Patent Office in a counterpart application, and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

Respectfully submitted,

Toshio MIYATA et al.

By 
Matthew M. Jacob
Registration No. 25,154
Attorney for Applicants

MJ/rlg
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
July 19, 2006

INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.
2006_0834ASERIAL NO.
10/581,255LIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)APPLICANT
Toshio MIYATA et al.

Date Submitted to PTO: July 19, 2006

FILING DATE
May 31, 2006

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AB	00/10606	03/2000	WO			

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AE	Maillard, L. C. et al., "Compt. Rend. Soc. Biol.", 1912, Vol. 72, p599
	AE	Miyata, T. et al., "Kidney Int.", 1999, Vol.55, p389-399
	AE	Esterbauer, H. et al., "Free Radic. Biol. Med.", 1991, Vol.11, p81-128
	AE	Anderson, M. M. et al., "J Clin. Invest.", 1997, Vol.99(3), p424-432
	AG	Sell, D. R. et al., "J. Biol. Chem." 1989, Vol.264(36), p21597-21602
	AH	Nakamura, K. et al., "J. Chem. Soc. Chem. Commun.", 1992, Vol.15, p992-994
	AI	Hayase, F. et al., "Biosci. Biotech. Biochem.", 1994, Vol.58(10), p1936-1937
	AJ	Njoroge, F. G. et al., "Carbohydr. Res.", 1987, Vol.167, p211-220
	AI	Ahmed, M. U. et al., "J. Biol. Chem.", 1986, Vol.261(11), p4889-4894
	AL	Hayase, F. et al., "Biosci. Biotech. Biochem.", 1995, Vol.59(8), p1407-1411

EXAMINER

/Marcos Sznajdman/

DATE CONSIDERED

01/08/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.S./

INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: July 19, 2006

ATTY DOCKET NO.
2006_0834ASERIAL NO.
10/581,255APPLICANT
Toshio MIYATA et al.FILING DATE
May 31, 2006

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	BK	Ahmed, M. U. et al., "Biochem. J.", 1997, Vol.324, p565-570					
	BL	Brinkmann, E. et al., "J. Chem. Soc. Perkin. Trans. 1", 1995, p2817-2818					
	BK	Wells-Knecht, K. J. et al., "J. Org. Chem.", 1995, Vol.60, p6246-6247					
	BL	Nagaraj, R. H. et al., "J. Biol. Chem.", 1996, Vol.271(32), p19338-19345					
	BF	Shipanova, I. N. et al., "Arch. Biochem. Biophys.", 1997, Vol.344(1), p29-36					
	BG	Neeper, M. et al., "J. Biol. Chem.", 1992, Vol.267(21), p14998-15004					
	BH	Suzuki, H. et al., "Nature", 1997, Vol.386, p292-296					
	BL	Vlassara, H. et al., "Molecular Medicine", 1995, Vol.1(6), p634-646					
	BL	Lander, H. M. et al., "J. Biol. Chem.", 1997, Vol.272(28), p17810-17814					
	BK	Chappey, O. et al., "Eur. J. Clin. Invest.", 1997, Vol.27, p97-108					
	BL	Yamagishi, S. et al., "Biochem. Biophys. Res. Commun.", 1995, Vol.213(2), p681-687					

EXAMINER

/Marcos Sznaidman/

DATE CONSIDERED

01/08/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.S./

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: July 19, 2006

ATTY DOCKET NO.
2006_0834ASERIAL NO.
10/581,255APPLICANT
Toshio MIYATA et al.FILING DATE
May 31, 2006

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA						

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

CK	Yamagishi, S. et al., "FEBS Lett.", 1996, Vol.384, p103-106
CE	Doi, T. et al., "Proc. Natl. Acad. Sci. USA", 1992, Vol.89, p2873-2877
CK	Horie, K. et al., "J. Clin. Invest.", 1997, Vol.100(12), p2995-3004
CE	Sugimoto, K. et al., "Diabetologia", 1997, Vol.40, p1380-1387
CE	Park, L. et al., "Nat. Med.", 1998, Vol.4(9), p1025-1031
CG	Miyata, T. et al., "J. Clin. Invest.", 1993, Vol.92, p1243-1252
CH	Smith, M. A. et al., "Proc. Natl. Acad. Sci. USA", 1994, Vol.91, p5710-5714
CK	Miyata, T. et al., "Biochem. Biophys. Res. Commun.", 1998, Vol.244, p45-49
CJ	Makita, Z. et al., "N. Engl. J. Med.", 1991, Vol.325(12), p836-842
CK	Bucala, R. et al., "J. Clin. Invest.", 1991, Vol.87, p432-438
CL	Vlassara, H. et al., "Proc. Natl. Acad. Sci. USA", 1994, Vol.91, p11704-11708

EXAMINER

/Marcos Sznaidman/

DATE CONSIDERED

01/08/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.S./

INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: July 19, 2006

ATTY DOCKET NO.
2006_0834ASERIAL NO.
10/581,255APPLICANT
Toshio MIYATA et al.FILING DATE
May 31, 2006

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	DA						

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	DB	Miyata, T. et al., "J. of Am. Soc. Nephrol.", 1996, Vol.7(8), p1198-1206
	DC	Sugiyama, S. et al., "J. of Am. Soc. Nephrol.", 1998, Vol.9, p1681-1688
	DD	Witko-Sarsat, V. et al., "Kidney Int.", 1996, Vol.49, p1304-1313
	DC	Canestrari, F. et al., "Acta Haematol.", 1994, Vol.91, p187-193
	DL	Ueda, Y. et al., "Biochem., Biophys. Res. Commun.", 1998, Vol.245, 785-790
	DI	Richard, M. J. et al., "Nephron", 1991, Vol.57, p10-15
	DI	Jadoul, M. et al., "Kidney Int.", 1999, Vol.55, p2487-2492
	DI	Miyata, T. et al., "Kidney Int.", 1997, Vol.51, p1170-1181
	DI	Ulbricht, R. J. et al., "Fund Appl. Toxic.", 1984, Vol.4, p843-853
	DI	Miyata, T. et al., "Kidney Int.", 2000, Vol.58, p425-435
	DL	Yamada, K. et al., "Clin. Nephrol.", 1994, Vol.42(6), p354-361

EXAMINER

/Marcos Sznaidman/

DATE CONSIDERED

01/08/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.S./

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: July 19, 2006

ATTY DOCKET NO.
2006_0834ASERIAL NO.
10/581,255APPLICANT
Toshio MIYATA et al.FILING DATE
May 31, 2006

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	EA						

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	ED	Miyata, T. et al., "Nephrol. Dial. Transplant.", 1997, Vol.12, p255-258
	ED	Edelstein, D. et al., "Diabetologia, 1992, Vol.35, p96-97
	ED	Hammes, H.P. et al., "Proc. Natl. Acad. Sci. USA", 1991, Vol.88, p11555-11558
	EE	Matsumoto, K. et al., "Biochem. Biophys. Res. Commun.", 1997 Vol.241(2), p352-354
	EE	Nakamura, S. et al., "Diabetes", 1997, Vol. 46, p895-899
	EG	Beisswenger, P. J. et al., "Diabetes, 1999, Vol. 48, p198-202
	ED	Thornalley, P. J. et al., "Endocrinol. Metab.", 1996, Vol.3, p149-166
	EI	
	ED	
	EI	
	EG	

EXAMINER

/Marcos Sznaidman/

DATE CONSIDERED

01/08/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.S./